Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Launched by TAOFEEK OWONIKOKO · Jul 6, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new drug called onvansertib to see how safe and effective it is for treating patients with relapsed small cell lung cancer (SCLC). This trial is specifically for people whose cancer has not responded to standard chemotherapy or who cannot tolerate it. Onvansertib works by blocking an enzyme that is often overactive in cancer cells, which helps them repair themselves. The trial is currently recruiting participants who are 18 years or older and have confirmed SCLC, measurable disease, and who have received limited prior chemotherapy treatments.

If you or a loved one joins this trial, you can expect to take onvansertib as a pill. You will be monitored closely for any side effects or changes in your condition. There are specific requirements to be eligible, including having normal organ function and being able to tolerate oral medications. Participants will also need to agree to use contraception if they are capable of becoming pregnant. Overall, this trial aims to explore a new treatment option for patients with small cell lung cancer who have limited choices left.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients must have histologically or cytologically confirmed small cell lung cancer
• • 2. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>20 mm with conventional techniques or as \>10 mm with spiral CT scan. See Section 8for the evaluation of measurable disease.
• • 3. Patient must have failed or found to be intolerant of standard frontline platinum-based regimens and not more than two lines of cytotoxic chemotherapy treatment in total for extensive stage disease. Maintenance immunotherapy counts as part of the frontline therapy, while prior chemotherapy for limited stage disease will not count toward this total if completed more than 12 months before initiation of protocol therapy. Retreatment with the original chemotherapy regimen for sensitive relapsed SCLC counts as a separate line of treatment.
• • 4. Adult patients with age \>18 years. Because no dosing or adverse event data are currently available on the use of arsenic trioxide in patients \<18 years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable.
• • 5. Ability to tolerate oral medicine
• • 6. ECOG performance status ≤2
• • 7. Patients must have normal organ and marrow function as pre-defined
• • 8. Negative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potential
• • 9. Women of child-bearing potential and men must agree to use adequate contraception.
• • 10. Ability to understand and the willingness to sign a written informed consent document.
• • 11. Both men and women and members of all races and ethnic groups are eligible for this trial.
• Exclusion Criteria:
• • 1. Treatment with chemotherapy (within 4 weeks; 6 weeks for nitrosoureas or mitomycin C); radiotherapy or biologic agents (within 2 weeks) prior to first dose of onvansertib or those persistent, clinically significant, grade ≥2 adverse events due to agents administered more than 4 weeks earlier.
• • 2. Patients may not be receiving any other investigational agents (Use of conventional external beam radiation therapy will be allowed during protocol therapy solely for palliation of localized painful lesions or bone lesions at risk of fracture provided the radiation field does not encompass any selected target lesions required for assessment).
• • 3. Patients with uncontrolled symptomatic brain metastases. Subjects with a history of central nervous system (CNS) metastases must have documentation of stable brain imaging after completion of definitive treatment and prior to first dose of Study Drug. Patients must be off or on a stable dose of corticosteroids (not more than 10mg prednisone or equivalent). Definitive treatment may include surgical resection, whole brain irradiation, and/or stereotactic radiation therapy.
• • 4. Patients with active GI disorders likely to impair the absorption of oral medications
• • 5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to onvansertib.
• • 6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• • 7. Patient with untreated or active HBV, HCV and HIV are ineligible. Patients on stable doses of antiretroviral for at least six months and undetectable viral load will be enrolled with prior approval of the study sponsor. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
• • 8. Patients who require ongoing treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug.
• • 9. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
• • 10. Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator.